Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure

12Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The dysregulated physical interaction between two intracellular membrane proteins, the sarco/endoplasmic reticulum Ca2+ ATPase and its reversible inhibitor phospholamban, induces heart failure by inhibiting calcium cycling. While phospholamban is a bona-fide therapeutic target, approaches to selectively inhibit this protein remain elusive. Here, we report the in vivo application of intracellular acting antibodies (intrabodies), derived from the variable domain of camelid heavy-chain antibodies, to modulate the function of phospholamban. Using a synthetic VHH phage-display library, we identify intrabodies with high affinity and specificity for different conformational states of phospholamban. Rapid phenotypic screening, via modified mRNA transfection of primary cells and tissue, efficiently identifies the intrabody with most desirable features. Adeno-associated virus mediated delivery of this intrabody results in improvement of cardiac performance in a murine heart failure model. Our strategy for generating intrabodies to investigate cardiac disease combined with modified mRNA and adeno-associated virus screening could reveal unique future therapeutic opportunities.

Cite

CITATION STYLE

APA

De Genst, E., Foo, K. S., Xiao, Y., Rohner, E., de Vries, E., Sohlmér, J., … Chien, K. R. (2022). Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-29703-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free